Evaluation of Two Live, Cold-Passaged, Temperature-Sensitive Respiratory Syncytial Virus Vaccines in Chimpanzees and in Human Adults, Infants, and Children

Ruth A. Karron, Peter F. Wright, James E. Crowe, Jr., Mary Lou Clements-Mann, Juliette Thompson, Mamodikoe Makhene, Roberta Casey, and Brian R. Murphy

Two live-attenuated, cold-passaged (cp), temperature-sensitive (ts) candidate vaccines, designated cpts530/1009 and cpts248/955, were attenuated, genetically stable, and immunogenic in chimpanzees and were highly attenuated for human adults. In respiratory syncytial virus (RSV)–seropositive children, cpts530/1009 was more restricted in replication than cpts248/955. In seronegative children, 10⁴ pfu of cpts248/955 was insufficiently attenuated, and a high titer of vaccine virus was shed (mean peak titer, 10⁴ pfu/mL), whereas 10⁴ pfu of cpts530/1009 was relatively attenuated and restricted in replication (mean peak titer, 10³ pfu/mL). At a dose of 10⁵ pfu, cpts530/1009 was immunogenic in seronegative children (geometric mean titer of RSV neutralizing antibodies, 1:724). Transmission of either vaccine to seronegative placebo recipients occurred at a frequency of 20%–25%. Of importance, vaccine viruses recovered from chimpanzees and humans were ts. In contrast to previous studies, this study indicates that live attenuated RSV vaccines that are immunogenic and phenotypically stable can be developed. Additional studies are being conducted to identify a live RSV vaccine that is slightly more attenuated and less transmissible than cpts530/1009.

Respiratory syncytial virus (RSV) is the leading cause of viral respiratory illness in infants and children throughout the world (reviewed in [1]) and is an important cause of severe respiratory illness in the elderly [2] and in immunocompromised patients [3]. In the United States, RSV infections account for ~90,000 hospitalizations of children each year [4]. The importance of RSV as a respiratory pathogen makes RSV vaccine development a priority [5]. Since an effective vaccine will need to provide protective immunity against RSV-associated lower respiratory tract illness (LRI) in young infants, RSV immunization will need to be initiated in the first month of life. It may be difficult to immunize this population effectively for several reasons. Young infants may respond poorly to an RSV vaccine because of immunologic immaturity and because maternally derived antibody may interfere with the immune response to the vaccine [1, 6–8]. Infants will also need to be immunized with a vaccine that protects against the antigenically divergent RSV subgroups A and B. Finally, it is likely that infants will need to be immunized several times to achieve a satisfactory level of immunity since even a single infection with wild type (wt) RSV does not completely protect against subsequent RSV-associated LRI [9, 10].

Efforts to produce a safe and effective RSV vaccine have been underway for >30 years. Early attempts yielded a formalin-inactivated vaccine that produced enhanced disease in some immunized RSV-naive infants when they were naturally infected with wt RSV during the subsequent RSV season [11, 12]. More recently, an RSV fusion (F) subunit vaccine has been produced that may prove useful in the elderly [13] but is unlikely to be administered to young infants. Adenovirus and vaccinia virus recombinants containing the RSV F and attachment (G) glycoproteins have also been developed but were not sufficiently immunogenic in chimpanzees to warrant clinical evaluation [14–16]. Live RSV vaccines might provide the best alternative for immunizing young infants. A live vaccine would mimic natural infection, induce a balanced cellular and humoral immune response, and be unlikely to produce enhanced disease [6]. In addition, live virus vaccines can replicate at mucosal surfaces even in the presence of passively acquired antibodies [7, 8, 17]. Previous live RSV candidate vaccines were either overly attenuated in young children [18–21], and those that were temperature-sensitive (ts) did not retain this phenotype during replication in vivo [22]. Recently, a series of live attenuated candidate vaccines was derived by chemical mutagenesis of an incompletely attenuated cold-passaged RSV mutant (cpRSV [23–25]). The parent virus,
Materials and Methods

Viruses. The isolation and characterization of wt RSV strain A2, of cpRSV, and of the ts mutants 248/955 (shutoff temperature, 37°C) and 530/1009 (shutoff temperature, 36°C) have been described [24–27]. Each of these ts mutants was derived independently from cpRSV by serial mutagenesis with 5-fluorouracil in Vero cell monolayer cultures. The ts mutants were biologically cloned by three plaque-to-plaque passages and amplified by four passages to prepare the vaccine pools. The wt RSV strain A2 (designated lot RSV M6) was prepared in MRC-5 cell monolayer cultures, and each of the progeny strains (cpRSV, lot A-11; cpts248/955, lot A-10; and cpts530/1009, lot A-16) were prepared in qualified Vero cell monolayer cultures. The cpRSV lot A-11 differed from the previously evaluated cpRSV [27] in that it was biologically cloned by three plaque-to-plaque passages in MRC-5 cell monolayer cultures. This cloned preparation of cpRSV served as the immediate parent for the ts derivative viruses. Virus suspensions for clinical trials were produced and found to be free of adventitious agents by Louis Potash (Dyncorp/PRI, Bethesda, MD). The titers of the wt RSV A2 strain and of cpRSV, cpts248/955, and cpts530/1009 were 10^9, 10^8, 10^7, and 10^5 pfu/mL, respectively. When necessary, the virus suspensions were diluted in L-15 medium (BioWhittaker, Walkersville, MD) immediately prior to use.

Studies in chimpanzees. Young male or female chimpanzees (Pan troglodytes) weighing 8.8–10.4 kg were pair-housed in large glass isolator suites and maintained as described previously [28]. The animals given cpts248/955 were on loan from the University of Texas MD Anderson Cancer Center (Bastrop). These chimpanzees lacked detectable serum neutralizing antibodies to RSV A2 (titer <1:10). Four seronegative chimpanzees were inoculated with cpts248/955 by both the intranasal and intratracheal routes with a dose of 10^5 pfu in a 1-mL inoculum at each site. Data from similar animals that received wt RSV strain A2, cpRSV, and cpts530/1009 were described previously [23, 25] and are presented here for the purpose of comparison. The comparability of the studies was insured by the use of identical protocols and challenge virus suspensions. In addition, inoculation, sampling, and clinical scoring procedures were performed by the same individuals in each study. Following inoculation of virus, nasopharyngeal swab specimens were collected while animals were under ketamine anesthesia for quantitation of the amount of virus shed on days 1–10, 13, 16, and 20, and tracheal lavage specimens were collected on days 2, 4, 6, 8, 10, 13, 16, and 20, as described previously [15]. Virus present in the respiratory tract secretions was quantified by plaque titration at 32°C, 39°C, and 40°C on HEp-2 cells as previously described. The amount of rhinorrhea was estimated daily and assigned a score of 0 to 4 by an experienced observer (0 = none, 1 = trace, 2 = mild, 3 = moderate, 4 = severe [29]). One month after immunization, animals were challenged with wt RSV A2 virus as previously described [25].

Clinical studies of adults. The RSV A2 wt virus, cpRSV, cpts248/955, and cpts530/1009 were each evaluated in open-label, nonrandomized trials in healthy adults 18–45 years of age who were not in contact with immunosuppressed individuals or infants <1 year of age. Ninety-nine adults participated in these studies: 44 received the RSV wt A2 virus, 20 each received the cpRSV or the cpts248/955 viruses, and 15 received cpts530/1009. The health of the adult volunteers was assessed as previously described [29]. The wt RSV A2 virus was evaluated in the Johns Hopkins University Center for Immunization Research (CIR) isolation unit. Volunteers were given 10^7 pfu of RSV A2 wt virus in 1 mL intranasally. Nasal washes to quantitate virus shedding were performed daily, once prior to inoculation and for 10 days after. Volunteers were examined each day, and their temperatures and vital signs were recorded every 6 h during the 13-day isolation period. Vaccine strains were evaluated in outpatient studies at the CIR. Volunteers who received 10^7 pfu of cpRSV, cpts248/955, or cpts530/1009 intranasally were examined on the day of inoculation and on days 4–8 following inoculation. On each study day (0–10), volunteers recorded their own oral temperatures twice and reported any respiratory or febrile illness to the study nurse. All subjects who reported illness were examined by a study investigator.

Clinical studies of children. After cpts248/955 and cpts530/1009 were shown to be well tolerated in adults, these strains were evaluated in randomized, double-blind, placebo-controlled phase I trials in infants and children 6–60 months of age at the CIR and at the Vanderbilt University Vaccine Center (VVC). Ninety children were enrolled in these phase I safety and immunogenicity studies: 40 participated in studies of cpts248/955 and 50 in studies of cpts530/1009. Children were eligible to participate in these studies if they were healthy and if all other household members and day care contacts were ≥1 year of age. Prior to enrollment, children were screened for level of RSV serum neutralizing antibody by a complement-enhanced, 60% plaque-reduction neutralization assay [30]; those with titers >1:40 were considered RSV-seropositive. Both vaccines were initially tested at a dose of 10^5 pfu in seropositive children and tested subsequently at a dose of 10^4 pfu (cpts248/955 strain) or at 10^5 or 10^6 pfu (cpts530/1009 strain) in seronegative children. Each subject received 0.5 mL of vaccine or placebo intranasally. In the pediatric studies, the ratio of vaccinees to placebo recipients was ~2:1. Seropositive study participants were examined 2 days before inoculation and for 9 days after. Seronegative study participants were examined 2 days
before and on days 1–9, 11, 14, 16, 18, 21, and 23 after inoculation; interval symptom histories were obtained from parents on days when the children were not examined. Children were observed for 1–2 h at the CIR and for 6–10 h at the VVC in a playroom setting on each study day. Respiratory and febrile illnesses were defined as fever (rectal temperature, ≥38.1°C), upper respiratory tract illness (URI; rhinorrhea or pharyngitis for ≥2 days), LRI (persistent wheezing or pneumonia), and cough (on ≥2 consecutive days) [31].

To assess the long-term safety of the cpts 248/955 and 530/1009 candidate vaccines, seronegative infants and children enrolled in these trials were followed through the subsequent RSV season. A group of RSV-seronegative children who did not receive vaccine or placebo were recruited as additional control subjects for this phase of the study. Children who participated in surveillance were monitored throughout the RSV season for fever and respiratory illnesses (as defined above). Nasal washes from ill children were tested for RSV by culture and by EIA (Testpack; Abbott Laboratories, Abbott Park, IL).

Isolation, quantitation, identification, and phenotypic characterization of virus. Nasal wash specimens for virus isolation were obtained on each day of observation from all subjects who participated in these studies. Fresh undiluted nasal wash specimens were titered by plaque assay on HEp-2 cell monolayer cultures maintained under a semisolid overlay at 32°C as previously described, and results were expressed as log_{10} pfu/mL [25]. Nasal wash samples were also inoculated into tubes containing Vero and HEp-2 cell culture monolayers. Virus isolates from these tubes were identified as RSV using an indirect IFA (Bartels Microscan; Baxter Healthcare, Bellevue, WA). For purposes of calculation, samples in which virus was not detected or did not produce plaques were assigned an infectivity titer of 10^0 pfu/mL.

Phenotypic characterization of virus isolates. To assess the stability of the ts phenotype, fresh nasal wash specimens from subjects who participated in trials of cpts248/955 and cpts530/1009 were titered at 32°C and 40°C, and a more extensive analysis of efficiency of plaque formation at 32°C, 38°C, 39°C, and 40°C was determined subsequently using frozen aliquots of nasal wash specimens as previously described [23–25].

Immunologic assays. Sera and nasal wash specimens for measurement of RSV-specific antibodies were obtained from adults and RSV-seropositive children before and 4 weeks after inoculation and from RSV-seronegative children before and 8 weeks after inoculation. Sera were tested for antibodies to RSV by plaque reduction neutralization assay and for IgG antibodies to RSV F and G glycoproteins by end-point titration in an ELISA using immunoadfinity-purified F and G glycoproteins from RSV A2 infected cell lysates [32, 33].

Nasal wash samples were also tested for the presence of IgA antibody to purified RSV F and G glycoproteins by ELISA. Each ELISA nasal wash anti-RSV F or G IgA titer was corrected to a total IgA concentration of 100 mg/mL as measured by a radial immunodiffusion assay (Binding Site, San Diego) as previously described [29].

Data analysis. Laboratory evidence of infection with an RSV wt or vaccine strain was defined as isolation of RSV, a ≥4-fold rise in serum RSV neutralizing antibody titer, and/or a ≥4-fold rise in serum IgG antibody titer to purified RSV F and/or G glycoproteins. In several persons, isolated serum responses to either RSV F or G glycoprotein were detected. In these instances, the ELISAs for both F and G glycoproteins were repeated and, if the response was confirmed, these individuals were considered to have been infected with the candidate vaccine virus. Isolated nasal wash antibody responses to RSV F or G glycoprotein were not considered definitive evidence of infection with vaccine virus.

RSV antibody titers were expressed as reciprocal mean log_2. The Mann-Whitney U test (two-tailed) was used to compare mean titers between groups. Rates of illness among vaccinees and placebo recipients were compared by two-tailed Fisher’s exact test.

Results

Response of RSV-seronegative chimpanzees to wt RSV A2, cpRSV, cpts248/955, or cpts530/1009. Of the viruses studied, cpts530/1009 was the most restricted in replication in the upper and lower respiratory tracts of seronegative chimpanzees (table 1). Of importance, the replication of both cpts248/955 and 530/1009 was highly restricted in the lower respiratory tract, suggesting that it would be safe to evaluate these vaccines in clinical trials. RSV cpts248/955 recovered from nasopharyngeal specimens (n = 30) and tracheal lavage specimens (n = 5) failed to produce plaques at 40°C, indicating that the cpts248/955 candidate vaccine, like the previously evaluated cpts530/1009 candidate vaccine, retained the ts phenotype after replication in seronegative chimpanzees [25]. The 4 chimpanzees that received the cpts248/955 candidate vaccine developed a moderate titer of neutralizing antibody (geometric mean titer, 1:478) and, like the chimpanzees that received the cpts530/1009 candidate vaccine, were completely resistant to challenge with wt RSV A2 virus [25].

Response of adult volunteers to wt RSV A2, cpRSV, cpts248/955, or cpts530/1009. cpRSV, cpts248/955, and cpts530/1009 replicated less well than wt virus in healthy adults (table 2). The 3 mutant viruses were less infectious than wt virus and were shed less frequently in these subjects (P = .01, .003, and .001 for cpRSV, cpts248/955, and cpts530/1009, respectively; Fisher’s exact test). Respiratory, febrile, or systemic illnesses also occurred less often in recipients of these attenuated strains than in recipients of wt RSV A2 (P = .006, <.001, and <.001 for cpRSV, cpts248/955, and cpts530/1009, respectively; Fisher’s exact test). Serum or nasal wash antibody responses to wt virus or vaccine were observed in about one-third of the study participants; the rate of response did not differ significantly between any of these groups (table 3). The attenuation of the cpts248/955 and 530/1009 candidate vaccines for healthy adults led us to evaluate these cpts viruses in RSV-seropositive children. The biologically cloned cpRSV was not evaluated in children because previous studies indicated that uncloned cpRSV was insufficiently attenuated in RSV-seronegative infants [19].

Response of RSV-seropositive children to cpts248/955 or cpts530/1009. The cpts248/955 and cpts530/1009 candidate vaccines were evaluated at a dose of 10^4 or 10^5 pfu in seroposi-
Table 1. Response of RSV-seronegative chimpanzees to intranasal and intratracheal infection with 10^4 pfu of wild type RSV A2, cpRSV, A2 cpts248/955, or cpts530/1009.

<table>
<thead>
<tr>
<th>RSV administered</th>
<th>No. of chimpanzees</th>
<th>No. infected</th>
<th>Rhinorrhea score mean (SD)</th>
<th>Mean peak titer* (SD) of virus in</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild type</td>
<td>4</td>
<td>4</td>
<td>1.4 (0.9)</td>
<td>5.5 (0.4) 5.7 (0.3)</td>
</tr>
<tr>
<td>cpRSV</td>
<td>2</td>
<td>2</td>
<td>0.6 (0.1)</td>
<td>4.6 (0.5) 2.9 (0.1)</td>
</tr>
<tr>
<td>cpts248/955</td>
<td>4</td>
<td>4</td>
<td>0.9 (0.2)</td>
<td>4.6 (0.8) 1.6 (1.6)</td>
</tr>
<tr>
<td>cpts530/1009</td>
<td>4</td>
<td>4</td>
<td>0.5 (0.3)</td>
<td>3.6 (0.5) 1.0 (0.6)</td>
</tr>
</tbody>
</table>

NOTE. For purposes of calculation, titer of 0.7 pfu/mL was assigned to culture-negative samples.

* Virus titers are expressed as log_{10} pfu/mL.

tive children (table 2). cpts248/955 infected the majority of vaccinees at each dose tested, and children who received 10^5 pfu of this candidate vaccine shed virus in titers as high as 10^{4.7} pfu/mL (mean, 10^{2.7}). In contrast, cpts530/1009 infected few vaccinees and was not recovered from any seropositive child, indicating that it was more attenuated than cpts248/955 for seropositive children. The absence of LRI in seropositive recipients of the cpts248/955 and 530/1009 candidate vaccines suggested that it was safe to continue the evaluation of these cpts viruses in RSV-seronegative children.

The local and systemic immune responses of seropositive children to each of these candidate vaccine viruses are shown in table 3. At the 10^5-pfu dose, a serum neutralizing or glycoprotein ELISA antibody response was observed in 62% of the vaccinees who received cpts248/955 and 31% of those who received cpts530/1009. Nasal antibody responses to either candidate vaccine were detected less frequently in these seropositive children. A single placebo recipient in the cpts248/955 vaccine study developed a 4-fold rise in serum antibody titer to the RSV F glycoprotein, which might have

Table 2. Clinical and virologic responses of adults and seropositive and seronegative children to wild type RSV A2, cpRSV, A2 cpts248/955, cpts530/1009, or placebo.

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Virus given (log_{10} pfu)</th>
<th>No. of subjects</th>
<th>% infected</th>
<th>% shedding Duration of shedding, mean (SD)</th>
<th>Peak titer, mean (SD) log_{10} pfu/mL</th>
<th>Virus isolation (nasal wash)</th>
<th>% with indicated illness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults</td>
<td>Wild type 3.9 44 50 43*</td>
<td>Wild type 3.9 44 50 43*</td>
<td>6.8 (2.8) 3.3 (1.5)</td>
<td>7 41 7 0 0 52</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cpRSV</td>
<td>5.0 20 30 10*</td>
<td>cpRSV 5.0 20 30 10*</td>
<td>2.7 (3.8) 1.7 (2.1)</td>
<td>5 10 0 0 5 15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>248/955</td>
<td>5.0 20 10 5</td>
<td>248/955 5.0 20 10 5</td>
<td>4.0 (4.0) 2.8 (2.2)</td>
<td>0 5 0 0 0 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>530/1009</td>
<td>5.0 15 33 0 0</td>
<td>530/1009 5.0 15 33 0 0</td>
<td>0 0 0 0 0 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children</td>
<td>Seropositive 248/955 4.0 6 67 17</td>
<td>Seropositive 248/955 4.0 6 67 17</td>
<td>5.3 (9.1) 1.1 (0.9)</td>
<td>67 67 0 0 0 17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>530/1009 4.0 5 0 0</td>
<td>530/1009 4.0 5 0 0</td>
<td>0 0 0 0 0 0</td>
<td>40 0 0 0 0 60</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>248/955 5.0 13 62 38</td>
<td>248/955 5.0 13 62 38</td>
<td>5.1 (4.0) 2.7 (1.8)</td>
<td>15 7 0 0 0 23</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>530/1009 5.0 13 31 0</td>
<td>530/1009 5.0 13 31 0</td>
<td>0 0 0 0 0 0</td>
<td>15 0 0 0 0 15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo²² 0.0 9 0 0</td>
<td>Placebo²² 0.0 9 0 0</td>
<td>0 0 0 0 0 0</td>
<td>44 0 0 0 0 11</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo³³ 0.0 7 0 0</td>
<td>Placebo³³ 0.0 7 0 0</td>
<td>0 0 0 0 0 0</td>
<td>14 0 0 0 0 14</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seronegative 248/955 4.0 8 88 88</td>
<td>Seronegative 248/955 4.0 8 88 88</td>
<td>9.0 (1.9) 4.4 (1.0)</td>
<td>80 88 12 25 25 100</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>530/1009 4.0 7 86 43</td>
<td>530/1009 4.0 7 86 43</td>
<td>4.8 (5.7) 2.0 (1.5)</td>
<td>57 71 0 0 0 71</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>530/1009 4.0 5 8100 100</td>
<td>530/1009 4.0 5 8100 100</td>
<td>11.0 (1.7) 4.5 (1.8)</td>
<td>62 62 12 0 38 88</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo²² 0.0 4 25 25</td>
<td>Placebo²² 0.0 4 25 25</td>
<td>23 37</td>
<td>75 100 0 25 0 100</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo³³ 0.0 10 20 10</td>
<td>Placebo³³ 0.0 10 20 10</td>
<td>8.0 (8.0) 1.2 (0.6)</td>
<td>40 60 10 0 20 80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NOTE. Six- to 60-month-old RSV-seropositive children and 6- to 36-month-old RSV-seronegative children were enrolled in these studies. For purposes of this study, seropositive children were those with RSV serum plaque-reduction neutralizing antibody titers >1:40. Infection was defined as described in text. URI, upper respiratory tract illness; LRI, lower respiratory tract illness. Duration of shedding is defined as last day on which vaccine virus was recovered.

* P = .01, † > .003, ‡ > .001; § > .006; ‰ < .001; ′ < .001.

²² = placebo recipients in studies of RSV A2 cpts48/955 virus.
³³ = placebo recipients in studies of RSV A2 cpts530/1009 virus.
resulted from transmission of vaccine virus from an infected vaccinee.

Response of RSV-seronegative children to cpts248/955 or cpts350/1009 vaccines. At a dose of 10^2 pfu, cpts248/955 was infectious and immunogenic but not sufficiently attenuated for RSV-seronegative infants and children (table 2). Eighty-eight percent of seronegative infants and children shed vaccine virus (mean peak titer, 10^4.4 pfu/mL). Respiratory or febrile illness or otitis media associated with shedding of cpts248/955 was observed in all infected children, 1 of whom also had a viral enanthem consistent with enterovirus infection. One child who received cpts248/955 had 3 days of LRI (wheezing) associated with viral shedding (figure 1). This child, who was treated as an outpatient, received nebulized bronchodilators and oral bronchodilators and steroids and recovered uneventfully. Because the cpts248/955 candidate vaccine retained the capacity to cause LRI, its clinical evaluation was terminated. This virus was also transmitted to a placebo recipient, who shed virus (10^1.7 pfu/mL) and had rhinorrhea and cough on days 21–23.

At a dose of 10^5 pfu, RSV cpts530/1009 was more attenuated than cpts248/955. The mean peak titer of virus shed by seronegative vaccinees was 10^2.0 pfu/mL, which was less than that shed by seronegative recipients of the cpts248/955 candidate vaccine (P = .01, Mann-Whitney U test). LRI was not observed in children who received 10^4 pfu of the cpts530/1009 candidate vaccine. At a dose of 10^6 pfu, clinical evaluation of cpts530/1009 was complicated by simultaneous infection with adenovirus in 3 vaccinees and 1 placebo recipient. LRI was observed in 3 vaccinees and 1 placebo recipient, who both shed adenovirus and cpts530/1009, but was not observed in other study participants. The cpts530/1009 mutant was apparently transmitted to this placebo recipient, who shed 10^1.7 pfu of vaccine virus on a single day (day 16) that did not coincide with her LRI (days 18–20). URI, low-grade fever, and otitis media occurred frequently but at approximately the same rate in vaccinees and placebo recipients (table 2).

The cpts248/955 and 530/1009 candidate vaccines were highly immunogenic in RSV-seronegative children (table 3). Rises in neutralizing or F or G antibody titers were detected in 88% of those who received 10^4 pfu of cpts248/955 and all of those who received 10^5 pfu of cpts530/1009. Nasal antibody responses were detected less frequently than serum antibody responses in these children, perhaps because of the insensitivity of the assay as compared with that of serologic assays.

A total of 23 seronegative vaccinees (8 of whom received cpts248/955 and 15 of whom received cpts530/1009) and 64 unvaccinated children (13 placebo recipients and 51 control unvaccinated children) were assigned to studies of RSV A2 cpts248/955 virus. Placebo recipients in studies of RSV A2 cpts248/955 were assigned to studies of RSV A2 cpts248/955 virus.
Figure 1. Response of seronegative vaccinee to $10^4$ pfu of RSV A2 cpts248/955 vaccine.

subjects) participated in RSV surveillance. Twelve (52%) of the vaccinees and 31 (48%) of the unvaccinated subjects were infected with wt RSV during surveillance. Of the infected vaccinees, all had URI, 2 had fever, 2 had otitis media, and one had LRI. The single subject with LRI (wheezing and crackles on auscultation) was a recipient of cpts530/1009 who did not shed vaccine virus but had developed a neutralizing antibody response to RSV. Of the infected unvaccinated subjects, all had URI, 11 had fever, 8 had otitis media, and 3 had LRI (all 3 children wheezed; 1 also had crackles on auscultation). Thus, there was no evidence of enhanced disease when recipients of these live RSV candidate vaccines were infected with wt RSV.

Phenotypic stability of the cpts248/955 and 530/1009 vaccines. Despite a moderate to high level of replication in the upper respiratory tracts of RSV-seropositive and -seronegative children, the cpts248/955 candidate vaccine retained the ts phenotype: Each of 40 nasal wash specimens containing virus produced plaques at 32°C but not at 40°C. Similarly, virus present in each of 71 specimens from vaccinees infected with the cpts530/1009 candidate vaccine retained the ts phenotype. The efficiency of plaque formation of virus present in the nasal washes of 5 cpts530/1009 vaccinees (table 4) indicated that little drift in the level of temperature sensitivity occurred during viral replication in fully susceptible children over an interval of 9–14 days.

Discussion

The strategy of passaging virus at low temperature to yield mutants that replicate efficiently at suboptimal temperature but are restricted in replication at core human body temperature has been used successfully to generate cold-adapted (ca) ts vaccines against influenza virus and parainfluenza virus type 3 (reviewed in [34], [35]). Earlier attempts to develop RSV vaccines that were either cp or ts were initially abandoned because of residual virulence for RSV-seronegative infants and because of the genetic instability of the RSV ts-1 mutant [1]. Recently, cpRSV was further mutagenized to generate a series of cpts vaccine candidates that were shown to be attenuated and genetically stable in mice and seronegative chimpanzees [15, 23–25]. The cpRSV evaluated in this study was a biologically cloned derivative of the cpRSV previously evaluated in the 1960s and 1970s. In the present study, we found that the cloned cpRSV, the immediate parent of the cpts vaccines, was attenuated in adults. This indicates that the biologically cloned cpRSV contains non-ts attenuating mutations that should be present in its cpts derivatives. Indeed, the cpts viruses sequenced to date contain the five nucleotide mutations [36] present in the biologically cloned cpRSV parent virus. Thus, one or more of these non-ts mutations attenuate cpRSV for chimpanzees and adults.

In this study, we also demonstrated that the cpRSV, cpts248/955, and cpts530/1009 viruses showed a progressive increase in attenuation for seronegative chimpanzees and adults. However, the cpts248/955 candidate vaccine was not sufficiently attenuated for fully susceptible (i.e., RSV-seronegative) children because it was shed in large quantities from the upper respiratory tract, temporally associated with rhinorrhea in 6 children and with LRI in 1 child, and transmitted to a placebo
Table 4. Characterization of the ts phenotype of virus recovered from 5 seronegative children who received 10<sup>6</sup> pfu of RSV A2 cpts530/1009 vaccine.

<table>
<thead>
<tr>
<th>Assay no.</th>
<th>Vaccinee no. or virus</th>
<th>Study day</th>
<th>Titer of virus in nasal aspirate (log&lt;sub&gt;10&lt;/sub&gt; pfu/mL) at indicated temperature (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>26591</td>
<td>32 38 39 40</td>
<td>3.8 &lt;0.7 &lt;0.7 &lt;0.7 4.6 &lt;0.7 &lt;0.7 3.8 5.2 &lt;0.7 &lt;0.7 6.5 3.6* &lt;0.7 &lt;0.7 4.5 1.1* &lt;0.7 &lt;0.7 4.6 &lt;0.7 &lt;0.7</td>
</tr>
<tr>
<td>2</td>
<td>26878</td>
<td>6 7 8 9 11</td>
<td>4.7 &lt;0.7 &lt;0.7 &lt;0.7 5.5 &lt;0.7 &lt;0.7 4.5 &lt;0.7 &lt;0.7 3.6 &lt;0.7 &lt;0.7 4.6 &lt;0.7 &lt;0.7 2.9 &lt;0.7 &lt;0.7 1.0 &lt;0.7 &lt;0.7</td>
</tr>
<tr>
<td>3</td>
<td>141</td>
<td>3 4 5 6 7 8 9 10 11 14</td>
<td>1.3 &lt;0.7 &lt;0.7 &lt;0.7 3.0 &lt;0.7 &lt;0.7 4.1 &lt;0.7 &lt;0.7 4.7 &lt;0.7 &lt;0.7 4.3 &lt;0.7 &lt;0.7 5.1 &lt;0.7 &lt;0.7 3.7 &lt;0.7 &lt;0.7 3.0 &lt;0.7 &lt;0.7</td>
</tr>
<tr>
<td>4</td>
<td>589</td>
<td>3 4 5 6 7 8 9 10 11</td>
<td>3.7 &lt;0.7 &lt;0.7 &lt;0.7 4.1 &lt;0.7 &lt;0.7 4.7 &lt;0.7 &lt;0.7 5.1 &lt;0.7 &lt;0.7 2.9 &lt;0.7 &lt;0.7 1.0 &lt;0.7 &lt;0.7 3.0 &lt;0.7 &lt;0.7</td>
</tr>
<tr>
<td>5</td>
<td>590</td>
<td>3 4 5 6 7 8 9 10 11</td>
<td>3.7 &lt;0.7 &lt;0.7 &lt;0.7 4.1 &lt;0.7 &lt;0.7 4.7 &lt;0.7 &lt;0.7 5.1 &lt;0.7 &lt;0.7 2.9 &lt;0.7 &lt;0.7 1.0 &lt;0.7 &lt;0.7 3.0 &lt;0.7 &lt;0.7</td>
</tr>
<tr>
<td>6</td>
<td>cpts530/1009</td>
<td>1 2 3 4 5 6 7 8 9 10 11</td>
<td>5.9 5.2 5.9 &gt;6.5 &gt;6.5 &gt;6.5 &gt;6.5 &gt;6.5 &gt;6.5 &gt;6.5</td>
</tr>
<tr>
<td>7</td>
<td>cpts530/1009</td>
<td>1 2 3 4 5 6 7 8 9 10 11</td>
<td>5.9 5.2 5.9 &gt;6.5 &gt;6.5 &gt;6.5 &gt;6.5 &gt;6.5 &gt;6.5 &gt;6.5</td>
</tr>
</tbody>
</table>

* Pinpoint plaque phenotype (<10% wild type plaque size at 32°C).
† Small plaque phenotype (<50% wild type plaque size at 32°C).

recipient. These studies suggest that RSV candidate vaccines, such as cpts248/955, that replicate to high titer in seropositive children may not be sufficiently attenuated for seronegative children. Evaluation of the cpts530/1009 candidate vaccine in seropositive children showed that this virus was more restricted in replication and more attenuated than cpts248/955. The clinical evaluation of cpts530/1009 in seronegative children was complicated by concurrent adenovirus infection in 4 subjects (and LRI in 2 subjects infected with both viruses); however, LRI was only observed in the children who shed adenovirus, which suggests that cpts530/1009 may be more attenuated than cpts248/955 in these susceptible children. Of importance, there was no evidence of disease enhancement when recipients of either of these live RSV candidate vaccines were infected with wt RSV.

The cpts248/955 vaccine was highly attenuated for chimpanzees and yet was able to cause LRI in seronegative children. This was an unexpected finding, and the reasons for this difference in response are not known. However, the relative order of attenuation of these viruses in chimpanzees (wt A2 virus being the most virulent, followed sequentially by cpRSV, cpts248/955, and cpts530/1009) was identical to that observed in our clinical studies, indicating that preclinical evaluation in chimpanzees provides valuable information about live RSV A vaccines destined for evaluation in humans.

In seronegative children, the cpts248/955 and 530/1009 candidate vaccines were highly infectious and immunogenic. The geometric mean titers of RSV neutralizing antibody achieved in recipients of 10<sup>4</sup> pfu of the 248/955 vaccine (1:776) and of 10<sup>5</sup> pfu of 530/1009 vaccine (1:724) were well above the level believed necessary to protect the lower respiratory tracts of susceptible infants [37]. It is hoped that similar levels of neutralizing antibodies might be induced in seronegative children with further attenuated cpts RSV vaccines, especially if more than one dose of vaccine is administered. These further attenuated cpts vaccines are, however, minimally infectious in adults and RSV-seropositive children, so it is likely that other vaccines will be needed to prevent serious RSV disease in the elderly and in RSV-seropositive children with chronic lung disease [2, 38].

The cpts248/955 and 530/1009 candidate vaccines were each recovered from a single seronegative placebo recipient. This is not surprising, since wt RSV spreads rapidly through susceptible populations [1, 9], and previous studies of the RSV ts-1 candidate vaccine showed that ts virus was recovered from a study nurse and a placebo recipient [18, 22]. In addition, some of the seronegative vaccinees in our studies shed virus in titers as high as 10<sup>2.9</sup> pfu/mL, which would likely exceed the dose required to infect a susceptible contact. Of note, the vaccine virus recovered from placebo recipients retained the ts phenotype. It may be that a live attenuated RSV vaccine, like live poliovirus vaccines, will retain the ability to spread to contacts, and studies of future live RSV candidate vaccines will need to address this possibility.

The stability of the ts phenotype of the cpts248/955 and 530/1009 candidate vaccines was assessed by determining the efficiency of plaque formation of virus present in 40 nasal wash specimens of those who received the 248/955 candidate vaccine and 71 nasal wash specimens of those who received the 530/1009 candidate vaccine. None of the virus present in the nasal washes produced plaques at 40°C, indicating that the ts phenotype was maintained despite vigorous replication of these viruses in the upper respiratory tracts of RSV-seronegative subjects. This is the first evidence that live RSV candidate vaccines
can be produced that maintain the ts phenotype after replication in seronegative children because previous studies of the RSV ts-1 vaccine in chimpanzees and young children showed that ts− revertant virus could be recovered from nasal wash specimens [18, 29]. It is not known why the cpts live RSV candidate vaccines have a more stable phenotype than RSV ts candidate vaccines. It may be that the stability of the ts phenotype in the cpts vaccines is augmented by additional non-ts attenuating mutations already present in the cp parent virus, as has been observed with cold-adapted influenza virus vaccines [39]. These findings are encouraging and provide the basis for continued development and evaluation of cpts candidate vaccines.

In summary, we have shown that live cpts RSV candidate vaccines can be produced that are phenotypically stable following replication in RSV-seronegative children. A further attenuated derivative of cpts RSV, cpts248/404, has been developed [25], and this vaccine may prove to be more restricted in replication and less transmissible than cpts530/1009. Evaluation of the cpts248/404 vaccine is in progress.

Acknowledgments

We thank Barbara Burns, Kathleen Gay, Anna Speaks, Bhagvanji Thumar, Sharon Tollefson, Ellen Davis, Jean Froehlich, and Denos Harris for expert clinical and technical assistance, Martin Blair for assistance with manuscript preparation, and Robert Chapman for review of the manuscript.

References


